Illumina Inc. v. BGI Genomics Co., Ltd.
Opinion
Trial Court Opinion
UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA 6 ILLUMINA INC., et al., Case No. 20-cv-01465-WHO
Plaintiffs,
ORDER GRANTING MOTION FOR
v. LEAVE TO AMEND
BGI GENOMICS CO., LTD., et al., Re: Dkt. Nos. 341, 342, 360, 375, 384 Defendants.
Plaintiffs Illumina, Inc. and Illumina Cambridge Ltd. (collectively “Illumina”) move for leave to amend their infringement contentions to add a literal infringement theory that the CoolMPS product infringes claims 1, 7, and 17 of its ’025 patent. Defendants BGI Genomics Co., Ltd., BGI Americas Corp., MGI Tech Co., Ltd., MGI Americas, Inc., and Complete Genomics Inc. (collectively “BGI”) oppose the motion, arguing that Illumina did not diligently seek leave to amend and that amendment would unfairly prejudice BGI. For the reasons discussed below, I conclude that Illumina has good cause to amend, that it acted with reasonable diligence in seeking leave to amend, and that amendment would not unduly prejudice BGI. Accordingly, Illumina’s motion for leave to amend…